艾日布林Halaven（eribulin mesylate）

[Jimin Pharmaceutical Guide] Eribulin Halaven is suitable for metastatic breast cancer. It was developed by Japan’s Eisai Pharmaceutical Company and is mainly used for breast cancer that has been treated with an anthracycline and a taxane and has metastasized.

This product is an injection with a specification of 0.44mg/ml. The recommended dose is 1.4mg/m2 intravenous injection, with injections on the first and eighth days of each course of 21 days.

In addition to monotherapy for metastatic breast cancer, Eribulin Halaven can also treat advanced liposarcoma, which is also called soft tissue sarcoma. It is a general term for a large class of malignant tumors that occur in soft tissues (fat, muscle, nerve, fibrous tissue, and blood vessels) throughout the body. Data show that there are about 75,000 confirmed cases of soft tissue sarcoma in the world, including 12,000 new cases in the United States, about 29,000 in Europe, and about 4,000 in Japan.